Neuropsychiatric consequences (atypical psychosis and complex-partial seizures) of ecstasy use: Possible evidence for toxicity-vulnerability predictors and implications for preventative and clinical care

Journal of Psychopharmacology

Volumn 17, Issue 3, 2003, Pages 342-345

  Vecellio, Marco ^a   Schopper, Christian ^a   Modestin, Jiri ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

3,4 methylenedioxyamphetamine; Case report; Complex partial epilepsy; Ecstasy; Fregoli syndrome; MDMA; Paranoid psychosis; Prevention; Side effects

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT;

ADDICTION; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN DYSFUNCTION; CASE REPORT; COMPLEX PARTIAL SEIZURE; DOSE RESPONSE; DRUG ABUSE; ELECTROENCEPHALOGRAM; EPILEPSY; FEMALE; HIGH RISK PATIENT; HUMAN; IATROGENIC DISEASE; MALE; NEUROLOGIC EXAMINATION; NEUROLOGICAL COMPLICATION; OPIATE ADDICTION; PARANOID PSYCHOSIS; PAROXYSMAL TACHYCARDIA; PERINATAL ASPHYXIA; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOSIS; SCHIZOPHRENIA; SYNDROME;

ADULT; AMPHETAMINE-RELATED DISORDERS; BEHAVIOR, ADDICTIVE; EPILEPSY; FEMALE; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROLOGIC EXAMINATION; PARANOID DISORDERS; SYNDROME;

EID: 0141481027     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/02698811030173018     Document Type: Article

References (33)

1. Bailly D (1999) Troubles neuropsychiatriques liés à la MDMA ('ecstasy') [Neuropsychiatric disorders due to MDMA ('ecstasy')]. Encephale 25: 595-602
2. Bango J, Fadon P, Mata F, Rubio G, Santo-Domingo J (1998) Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports. Actas Luso Esp Neurol Psiquiatr Cienc Afines 26: 260-263
3. Bell D S (1965) Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 111: 701-707
4. Bilke O (1998) Ecstasy-Konsumenten: Motivationsmuster, Folgen und Therapie [Ecstasy consumers: patterns of motivation, consequences and therapy]. Psycho 24: 418-422
5. Boot B P, McGregor I S, Hall W (2000) MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 355: 1818-1821
6. Bowers M B (1977) Psychoses precipitated by psychotomimetic drugs. Arch Gen Psychiatry 34: 832-835
7. Bundesamt für Gesundheit (BAG) (1998) Ecstasy (MDMA). Eine Standortbestimmung [Ecstasy (MDMA). A position finding]. Bulletin BAG 49: 3-4
8. Carroll K M, Rounsaville B J (1993) History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 34: 75-82
9. Croft R J, Klugman A, Baldeweg T, Gruzelier J H (2001) Electrophysiological evidence of serotonergic impairment in long-term MDMA ('Ecstasy') users. Am J Psychiatry 158: 1687-1692
10. Curran H V (2000) Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodológical problems in research. Neuropsychobiology 42: 34-41
11. Curran H V, Travill R A (1997) Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. Addiction 92: 821-831
12. Dafters R I, Duffy F, O'Donell P J, Bonquet C (1999) Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology 145: 82-90
13. Davies N, Russell A, Jones P, Murray R M (1998) Which characteristics of schizophrenia predate psychosis? J Psychiatry Res 32: 121-131
14. Ellis H D, Luaute J P, Retterstol N (1994) Delusional misidentification syndromes. Psychopathology 27: 117-120
15. Enderlin V E, Meier-Abt P J, Kupferschmidt H (1999) Intoxikation durch Ecstasy und andere synthetische Drogen [Intoxication with ecstasy and other synthetic drugs]. Der informierte Arzt/Gazette Medicale 20: 346-352
16. Franken, I H (2001) Prevalence of MDMA (ecstasy) use and neurotoxicity. Eur Psychiatry 16: 508-509
17. Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18: 319-327
18. Henry J A, Jeffreys K J, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (ecstasy). Lancet 340: 384-387
19. Hollister L E (1988) Cannabis - 1988. Acta Psychiatr Scand 78: 108-118
20. Holmes S B, Banerjee A K, Alexander W D (1999) Hyponatraemia and seizures after ecstasy use. Postgrad Med J 75: 32-34
21. Laviola G, Adriani W, Terranova M L, Gerra G (2000). Fattori psicobiologici di rischio e vulnerabilità agli psicostimolanti in soggetti adolescenti e modelli animali [Psychobiologic risk factors and vulnerability to psychostimulants in adolescents and animal models]. Ann Ist Super Sanita 36: 47-62
22. Liechti M E, Vollenweider FX (2000). The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacology 14: 269-274
23. Modestin J, Nussbaumer C, Angst K, Scheidegger P, Hell D (1997) Use of potentially abusive psychotropic substances in psychiatric inpatients. Eur Arch Psychiat Clin Neurosci 247: 146-153
24. Niedermeyer E (1984) Neurologic aspects of the epilepsies. In Blumer D (ed.), Psychiatric aspects of epilepsy. American Psychiatric Press, Washington
25. Poulin C, Elliott D (1997) Alcohol, tobacco and cannabis use among Nova Scotia adolescents: implications for prevention and harm reduction. Can Med Assoc J 156: 1387-1393
26. Ramamoorthy Y, Yu A, Suh N, Haining R L, Tyndale R F, Sellers E M (2002) Reduced (±)-3,4-methylenedioxymethamphetamine metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 63: 2111-2119
27. Rattray M (1991) Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem 26: 77-87
28. Sakurai Yamashita Y, Kataoka Y, Fujiware M, Mihe K, Veki S (1989) Delta-9-tetrahydrocannabinol facilitates striatal dopaminergic transmission. Pharmacol Biochem Behav 33: 397-400
29. Solowij N (1993) Ecstasy (3,4-methylenedioxymethamphetamine). Curr Opin Psychiatry 6: 411-415
30. Theune M, Esser W, Druschky K-F, Interschick E, Patscheke H (1999) Grand-mal-Serie nach Ecstasy-Einnahme [Series of grand-mal seizures following ecstasy intake]. Nervenarzt 70: 1094-1097
31. Thomasius R, Schmolke M, Kraus D (1997) MDMA ('Ecstasy')-Konsum - ein Überblick zu psychiatrischen und medizinischen Folgen [MDMA ('Ecstasy') consume - a survey of psychiatric and medical effects]. Fortschr Neurol Psychiat 65: 49-61
32. Vaiva G, Bailly D, Boss V, Thomas P, Lestavel P, Goudemand M (2001) Un cas d'épisode psychotique aigu après prise unique d'ecstasy [A case of acute psychotic episode following a single dose of ecstasy]. Encephale 27: 198-202
33. Vollenweider F X, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ('Ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241-251